GLP-1 pills are here: What does it mean for employers?
Will GLP-1 pills change how employers approach coverage? It’s an important question, but the answer isn't so straightforward.
Rae McMahan, SVP of Payer Solutions, shared why these medications are pushing employers to look beyond cost to efficacy and long-term outcomes in SHRM. The similar pricing to injectables is revealing a coordination gap that is driving employers to shift toward more direct, transparent, and real-time drug access models.
“These drugs are amazingly effective for managing diabetes and helping with weight loss,” she said. “I think employers will look at cost, efficacy and health outcomes to determine whether covering these medications makes sense.”
GLP-1s represent a huge opportunity for employers to provide access to innovative drugs in a sustainable way. See the full article in SHRM, and learn more about Prescryptive’s insights around GLP-1s and our unique approach to access through Centers of Excellence.